A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease

A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease

This study is being done for the following reasons:

To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one dose is given to healthy participants and participants diagnosed with Alzheimer's disease. It will also look at how safe and tolerable the study drug is when given to healthy participants in higher doses.

This research study is being conducted in three groups, referred to as Groups (Cohorts) A, B, or C.

Group A will enroll participants with Alzheimer's disease while Groups B and C will enroll healthy participants.

For Group A or B, participation in this research study could last up to 34 days. For Group C, participation could last up to 60 days.

Study Overview

• Status: Completed
• Conditions: Alzheimer Disease; Healthy Volunteers
• Intervention / Treatment: Drug: Placebo; Drug: LY2886721

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy participants have a body mass index (BMI) of 19 to 32 kilograms per square meter (kg/m^2), inclusive, at screening. There are no restrictions on BMI in participants diagnosed with Alzheimer's disease.
• Healthy participants should not be taking any concomitant medications. For participants with Alzheimer's disease, concomitant medications will be determined by the investigator in consultation with the Lilly clinical pharmacologist on an individual basis.

Cohort A:

• Participants are defined as otherwise healthy males or females as determined by medical history and physical examination, and a diagnosis of Alzheimer's disease and must be at least 45 years of age.
• Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's disease, as determined by a clinician approved by the sponsor or designee.
• Mini Mental State Examination (MMSE) score of 16 through 28 at screening.
• Modified Hachinski Ischemia Scale (MHIS) score of <4.
• Capable of understanding and signing their own informed consent, in the opinion of the investigator, or if the participant has a Legally Authorized Representative (LAR), then the LAR must be capable of understanding and signing the assent form, and the participant may or may not sign the informed consent, as to be determined by the investigator.
• If receiving concurrent treatment with an acetylcholinesterase inhibitor (AChEI) and/or memantine, the participant has been on a stable dose for at least 4 weeks before Day 1. Dosing must remain stable throughout the study. Note: If a participant has recently stopped ACHEIs and/or memantine, he or she must have discontinued treatment for at least 4 weeks before Day 1.

Exclusion Criteria:

• Have an abnormality in the 12-lead electrocardiogram (ECG).
• Have abnormal blood pressure.
• Have abnormal thyroid function as reflected by thyroid stimulating hormone (TSH) values outside of the normal range.
• Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.
• Show evidence of hepatitis C and/or positive hepatitis C antibody.
• Have had multiple episodes of head trauma, or have a history within the last 5 years of a serious infectious disease affecting the brain.
• Have chronic hepatic disease.
• Have evidence or history of significant active bleeding or a coagulation disorder.
• Cohort A: have any neurological disorders other than Alzheimer's disease.
• For healthy participants (Cohorts B and C) only: Use or intend to use over the- counter or prescription medication, including herbal medications within 14 days prior to dosing or during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A: 70 mg LY2886721; Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.	Drug: LY2886721
Placebo Comparator: Cohort A: Placebo; Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).	Drug: Placebo
Experimental: Cohort B: 70 mg LY2886721; Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.	Drug: LY2886721
Placebo Comparator: Cohort B: Placebo; Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).	Drug: Placebo
Experimental: Cohort C: 280 mg LY2886721; Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.	Drug: LY2886721
Placebo Comparator: Cohort C: Placebo; Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721	AUC0-∞ following administration of a single dose of 70 or 280 mg LY2886721.	Predose through 96 hours after administration of study drug
Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721	Cmax following administration of a single dose of 70 or 280 mg LY2886721.	Predose through 96 hours after administration of study drug
Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Cerebrospinal Fluid (CSF) LY2886721	AUC0-∞ following administration of a single dose of 70 mg LY2886721.	Predose through 36 hours after administration of study drug
Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721	Cmax following administration of a single dose of 70 mg LY2886721.	Predose through 36 hours after administration of study drug
Pharmacodynamics (PD): Cnadir of Plasma Amyloid β (Aβ)1-40	Plasma concentration of Aβ1-40 was summarized based on lowest observed concentration (Cnadir).	Predose, up to 96 hours after administration of study drug
PD: Cnadir of CSF Aβ 1-40	Plasma concentration of Aβ1-40 was summarized based on Cnadir following administration of a single dose of 70 mg LY2886721 or a single dose of LY2886721-matching placebo.	Predose up to 36 hours after administration of study drug

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cohort C: Mean QTcF Value at Cmax	The mean QTcF value at Cmax for participants administered a single dose of 280 mg LY2886721 was reported. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Time matched mean change from baseline in QTcF = time matched plasma concentration + participant + random error.	Predose up to 48 hours after administration of study drug

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start: March 1, 2013
• Primary Completion (Actual): May 1, 2013
• Study Completion (Actual): May 1, 2013

Study Registration Dates

• First Submitted: March 6, 2013
• First Submitted That Met QC Criteria: March 6, 2013
• First Posted (Estimate): March 8, 2013

Study Record Updates

• Last Update Posted (Actual): July 19, 2019
• Last Update Submitted That Met QC Criteria: May 9, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease
• Other Study ID Numbers: 15107 (CTSRMC, Abramson Cancer Center, University of Pennsylvania); I4O-EW-BACX (Other Identifier: Eli Lilly and Company)